Adding a statement that an overhaul of its OTC drug monograph program didn’t affect the US Food and Drug Administration’s oversight of homeopathic drugs is the biggest change between the agency’s draft and final guidances on regulating the Rx and OTC products.
The guidance the FDA published on 7 November presents the same descriptions of six areas of enforcement priorities –...




